The quadruplet regimen of daratumumab (Darzalex), lenalidomide (Revlimid), ixazomib (Ninlaro), and dexamethasone (D-RId) showed promising progression-free survival (PFS) and overall survival (OS) for patients with newly diagnosed multiple myeloma who... [7796 chars].. reed more
